DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION

Expression features of markers associated with differentiation (CD3, CD4, CD8, CD16) and activation (CD25, CD71, CD95 and HLA-DR) were studied on lymphocytes from patients of reproductive and postmenopausal age with ovarian cancer (FIGO clinical stages I to IV). Absolute lymphopenia, which was more...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	I. I. Antoneeva
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	ovarian cancer biomarkers lymphocytes tumor progression Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/401d5810cdbf44b282b374f1c388bc5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:401d5810cdbf44b282b374f1c388bc5e
record_format	dspace
spelling	oai:doaj.org-article:401d5810cdbf44b282b374f1c388bc5e2021-11-18T08:03:39ZDIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION1563-06252313-741X10.15789/1563-0625-2007-6-649-652https://doaj.org/article/401d5810cdbf44b282b374f1c388bc5e2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/260https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XExpression features of markers associated with differentiation (CD3, CD4, CD8, CD16) and activation (CD25, CD71, CD95 and HLA-DR) were studied on lymphocytes from patients of reproductive and postmenopausal age with ovarian cancer (FIGO clinical stages I to IV). Absolute lymphopenia, which was more pronounced in postmenopause, was found to be increased in the course of tumor progression. Moreover, the numbers of CD8+ cells significantly increased since early stages of disease, along with decreased amounts of CD3+ andCD4+ cells. CD16 expression was elevated at later stages, being sufficiently higher in postmenopausal patients. CD25 cell scores was increased at all clinical stages, and did not significantly differ in reproductive vs menopausal age. CD95+ cell number was increased, and it proved to be maximal at stage III-IV of the disease. The numbers of CD71+ cells was increased at all clinical stages of disease, being significantly higher in reproductive period, as compared with menopause. Expression of HLA-DR molecules on lymphocytes was enhanced at early stages of disease followed by significant decrease at stage IV of disease. Hence, phenotypic features of lymphocytes from the patients with ovarian cancer exhibit dynamic variability at different stages of tumor growth, being also dependent on reproductive vs. postmenopausal period.I. I. AntoneevaSPb RAACIarticleovarian cancerbiomarkerslymphocytestumor progressionImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 9, Iss 6, Pp 649-652 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	ovarian cancer biomarkers lymphocytes tumor progression Immunologic diseases. Allergy RC581-607
spellingShingle	ovarian cancer biomarkers lymphocytes tumor progression Immunologic diseases. Allergy RC581-607 I. I. Antoneeva DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION
description	Expression features of markers associated with differentiation (CD3, CD4, CD8, CD16) and activation (CD25, CD71, CD95 and HLA-DR) were studied on lymphocytes from patients of reproductive and postmenopausal age with ovarian cancer (FIGO clinical stages I to IV). Absolute lymphopenia, which was more pronounced in postmenopause, was found to be increased in the course of tumor progression. Moreover, the numbers of CD8+ cells significantly increased since early stages of disease, along with decreased amounts of CD3+ andCD4+ cells. CD16 expression was elevated at later stages, being sufficiently higher in postmenopausal patients. CD25 cell scores was increased at all clinical stages, and did not significantly differ in reproductive vs menopausal age. CD95+ cell number was increased, and it proved to be maximal at stage III-IV of the disease. The numbers of CD71+ cells was increased at all clinical stages of disease, being significantly higher in reproductive period, as compared with menopause. Expression of HLA-DR molecules on lymphocytes was enhanced at early stages of disease followed by significant decrease at stage IV of disease. Hence, phenotypic features of lymphocytes from the patients with ovarian cancer exhibit dynamic variability at different stages of tumor growth, being also dependent on reproductive vs. postmenopausal period.
format	article
author	I. I. Antoneeva
author_facet	I. I. Antoneeva
author_sort	I. I. Antoneeva
title	DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION
title_short	DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION
title_full	DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION
title_fullStr	DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION
title_full_unstemmed	DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION
title_sort	differentiation- and activation-associated markers of peripheral blood lymphocytes in the patients with ovarian cancer in the course of tumor progression
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/401d5810cdbf44b282b374f1c388bc5e
work_keys_str_mv	AT iiantoneeva differentiationandactivationassociatedmarkersofperipheralbloodlymphocytesinthepatientswithovariancancerinthecourseoftumorprogression
_version_	1718422538038542336

DIFFERENTIATION- AND ACTIVATION-ASSOCIATED MARKERS OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PATIENTS WITH OVARIAN CANCER IN THE COURSE OF TUMOR PROGRESSION

Ejemplares similares